Pandemic Assistance Core

流行病援助核心

基本信息

批准号：
10514267
负责人：
Catherine A Blish
金额：
$ 559.9万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-16 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514267
关键词：
2019-nCoV A549 ACE2 Adult Air Antiviral Agents Biological Models COVID-19 therapeutics Cell Line Cells Chikungunya virus Complex Data Development Distal Dose Drug Screening Evaluation Family Picornaviridae Flaviviridae Flavivirus GS-441524 Goals Histopathology Human In Vitro Individual Industry Infection Inflammation Infrastructure Inhalation Life Cycle Stages Liquid substance Lung Middle East Respiratory Syndrome Coronavirus Modeling Morbidity - disease rate Nasal Epithelium No-Observed-Adverse-Effect Level Oral Organoids Outpatients Pathway interactions Pharmaceutical Preparations Physiological RNA Viruses Research Personnel Resources Rodent Model SARS coronavirus SARS-CoV-2 variant Series Structure System TMPRSS2 gene Testing Therapeutic Therapeutic Index Tissues Togaviridae Toxic effect Translations Universities Viral Virus Virus Diseases Virus Replication West Nile virus Work antiviral drug development drug candidate drug development drug efficacy efficacy validation experience in vivo in vivo Model in vivo evaluation indexing innovation lead candidate mortality novel therapeutics pandemic disease pathogen programs prophylactic pulmonary function remdesivir screening subcutaneous synergism targeted treatment therapeutic candidate tool virology

项目摘要

PROJECT SUMMARY/ABSTRACT The Pandemic Assistance Core will enable investigators in this AViDD center to rapidly develop antiviral therapeutics for SARS-CoV-2 and other RNA viruses of pandemic potential. This core will provide capacity for rigorous in vitro and in vivo testing of compounds developed across all seven Projects, with a particular emphasis on providing unparalleled BSL3 and ABSL3 capacity. We will quickly and efficiently refine our targets and down-select from a series of go/no-go decisions over the course of our project, providing a funnelling structure to rapidly identify the most promising candidates both in vitro and in vivo. Compounds will be tested in both prophylactic and therapeutic models. As our Projects take unique approaches to target the viral life cycle, lead candidates from each project will also be tested in combination to identify synergism. The most promising of the lead candidates will then be sent for further development within the Translation Accelerator Core. To achieve this work we have brought together an outstanding and interdisciplinary team of investigators with significant experience in virology, drug development, and rodent models for drug screening. We also bring highly innovative approaches to test compounds in physiologic systems using human air-liquid interface (ALI) models and human adult lung organoids (ALO). We aim to provide industry-level capacity for screening and selecting the most promising drug candidates.

项目摘要/摘要大流行援助核心将使这个Avidd中心的研究人员能够快速发展抗病毒 SARS-COV-2和其他大流行潜力的RNA病毒的治疗剂。该核心将为在所有七个项目中开发的化合物的严格体外和体内测试强调提供无与伦比的BSL3和ABSL3容量。我们将迅速有效地完善我们的目标并在我们项目的整个过程中从一系列GO/NO-GO的决定中进行了选择，提供了漏斗结构可以快速识别体外和体内最有希望的候选人。化合物将在预防性和治疗模型。当我们的项目采用独特的方法来针对病毒生命周期时，每个项目的主要候选人也将组合测试以识别协同作用。最有前途的然后，将派遣主要的候选人，以在翻译加速器核心内进一步开发。到实现这项工作，我们将一个杰出和跨学科的调查人员团队与在病毒学，药物开发和啮齿动物筛查模型方面的重要经验。我们也带来使用人类空气界面（ALI）在生理系统中测试化合物的高度创新方法模型和人类成人肺器官（ALO）。我们旨在提供筛查和选择最有希望的候选毒品。